Arctic Securities acted as Joint Bookrunner in relation to the fully underwritten Rights Issue of 12,000,000 new shares in PCI Biotech Holding ASA. Through the Rights Issue, PCI Biotech will receive gross proceeds of NOK 360 million, which will enable the Company to perform the fimaChem pivotal study, as well as further develop its pipeline.
PCI Biotech is a cancer focused biopharmaceutical company developing therapeutic products based on its proprietary photochemical internalization (PCI) technology. The PCI technology works by inducing triggered endosomal release and may be used to unlock the true therapeutic potential of a wide array of modalities. One bile duct cancer study is currently in clinical development. The company is also developing PCI as a CTL induction technology for therapeutic and prophylactic vaccination.
We thank PCI Biotech for the vote of confidence and congratulate on the transaction.